Recently, the first leukemia CAR-T therapy drug in China with fully independent intellectual property rights, Nakiolenza Injection, entered the first batch of commercial insurance innovative drug catalogs. This is one of the original innovative major achievements of the Institute of Hematology, Chinese Academy of Medical Sciences (hereinafter referred to as "the Institute"). In the continuous expansion of indications, it has become the only cell therapy drug currently covering leukemia and lymphoma. The Fourth Plenary Session of the 20th Central Committee of the Communist Party of China emphasized the need to strengthen original innovation and key core technology research and development, and promote the deep integration of scientific and technological innovation and industrial innovation. In recent years, the Hematology Research Institute has systematically analyzed new trends, challenges, and opportunities in the development of the discipline. Through the construction of a platform for basic research and clinical translation, it has promoted breakthroughs in basic research, improved clinical diagnosis and treatment levels, and the transformation of scientific and technological achievements, achieving a series of internationally influential landmark achievements. Carrying out high-quality clinical research and cultivating breakthrough original achievements, the first gene therapy product in China for hemophilia B patients was launched in May last year. The AAV (adeno-associated virus) vector used in the first gene therapy product is a composite innovative vector. ”As a review expert, Ma Jun, director of Harbin Institute of Hematology and Oncology, stated that Professor Zhang Lei's team at the institute has conducted long-term research on the transformation and clinical validation of this groundbreaking innovative product. It is thanks to the team's rigorous research and accumulation over the years that the clinical research data of this product is detailed and authoritative, and its efficacy can withstand practical testing. Many original innovative drugs are conditionally marketed when approved, and their effectiveness and safety still need to be continuously verified after being marketed. Since 2019, the Hematology Research Institute team has continuously conducted a large number of clinical studies, including single center, multi center, and long-term follow-up, providing strong evidence of the safety and effectiveness of treating hemophilia B patients, and helping the new drug to be approved for unconditional marketing authorization during the review process. This is one of the typical representatives of drug clinical trial projects led by the Institute of Hematology. Data shows that the Institute has conducted 309 clinical trials, ranking first among medical institutions in the field of hematology in China. As a national clinical research center for hematological diseases, the Institute of Hematology not only tackles the bottleneck problem in the diagnosis and treatment of hematological diseases, but also promotes the construction of a standardized clinical research system, implements standardized management of medical data, establishes specialized disease standard datasets and dynamic specialized disease databases, and forms an iteratively updated specialized disease queue to provide support for high-quality clinical research. High quality clinical research is the foundation for the marketing of innovative drugs. Data shows that during the 14th Five Year Plan period, 28 domestically produced innovative drugs for hematological diseases were launched, with over 700 authorized patents, a six fold increase compared to the previous five years. We have developed a new algorithm and embedded a conditional autonomous AI model into the hospital information system to promote the "dual upgrade" of clinical diagnosis and basic research, and to evaluate the diagnostic and therapeutic effects of stem cell transplantation patients, which faces the challenges of "few samples, multiple variables, and uneven data collection". General algorithms are difficult to apply. ”Jiang Erlie, Vice President of the Hematology Research Institute and Director of the Stem Cell Transplantation Center, told Science and Technology Daily reporters that the "Tianjin Model" of hematopoietic stem cell transplantation was born in 1986, achieving China's first autologous bone marrow hematopoietic stem cell transplantation. Through technological updates and improvements, the Hematology Research Institute has continuously improved the "Tianjin model", which not only significantly enhances the efficacy of autologous transplantation, but also expands the work of allogeneic transplantation. The rapid development of technology has led the Hematology Research Institute to focus on artificial intelligence models. We have a solid database foundation, and by utilizing AI effectively, we can uncover patterns and provide precise assistance for the entire process of stem cell transplantation, including post transplant complication management and immune reconstruction monitoring. ”Jiang Erlie introduced that Professor Chen Junren from the Institute of Hematology, with the assistance of his self-developed AI model, reads multidimensional data from patients' bodies every day to determine the adjustment plan for immunosuppressants. With the assistance of AI management, the incidence of severe acute graft-versus-host disease in patients has significantly decreased from 16% to 5.5%. With the help of artificial intelligence models and through independent development and clinical optimization, the "Tianjin Model" of hematopoietic stem cell transplantation, which has a history of 40 years, has acquired intelligent "genes" and is moving towards a "no man's land" for human blood cell research in basic research. In May 2025, the recruitment for the "Blood Ecology Billion Cell Multiomics Program" will begin. AI can achieve automated analysis of blood cell morphology through deep learning, especially by combining single-cell multi omics technology. The blood cell atlas will continue to achieve refined iterations. ”Cheng Tao, an academician of the CAE Member and president of the Institute of Hematology, said that it was one of the key tasks during the "Tenth Five Year Plan" period to jointly promote the big science plan and build a national level medical resource bank and big data center for blood diseases through cooperation with all parties. In the future, the medical technology innovation model that closely integrates basic, clinical, and translational aspects will continue to provide new theories, technologies, and strategies for the field of hematology, improve the level of prevention and treatment of blood diseases in China, and meet the rapidly increasing demand for diagnosis and treatment of blood diseases. One of the main goals proposed in the 15th Five Year Plan is to significantly enhance basic research and original innovation capabilities. We are currently in an important window period of accelerated iteration and profound transformation of innovation paradigms in global medical technology. Deng Haihua, Secretary of the Party Committee and Vice President of Peking Union Medical College, Chinese Academy of Medical Sciences, emphasized that the Institute of Hematology has always adhered to the mission of being a "national team", leading the scientific and technological innovation of the hematology discipline, and promoting the coordinated leap of basic research, clinical treatment, and achievement transformation. (New Society)